MarketPeel
Insider Trading Intelligence
ND

Nathalie Dubois-stringfellow

SGMO
SVP-CHIEF DEVELOPMENT OFFICER · SANGAMO THERAPEUTICS, INC · CIK 0001947007
FILING MIX · LIFETIME19%/81%
BUYS
6
SELLS
25
TOTAL VALUE
$387.4K
COMPANIES
1
ACTIVE SINCE
Feb 2023
HOLDINGS NOW
332,769
AVG SELL PX
$0.57
TRADE KIND
SHOWING 31 / 31
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by Nathalie Dubois-stringfellow, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-23.08%+1.08%-24.16%-24.16%
14d1+100.00%-57.69%+2.80%-60.49%-60.49%
30d1+100.00%-42.31%
60d1+100.00%-34.62%+6.06%-40.67%-40.67%
90d1(1 pending)
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SGMO · 332,769 shares · as of Apr 21, 2026
0214,168428,336642,504856,672202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 6 buys / 25 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
345,942$0.26$89.2K332,769Apr 21, 2026Apr 23, 2026View →
SGMO
SANGAMO THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
800,000800,000Apr 1, 2026Apr 3, 2026View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
12,354$0.47$5.8K678,711Feb 25, 2026Feb 26, 2026View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
2,063$0.47$975691,065Feb 24, 2026Feb 26, 2026View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
36,676$0.40$14.6K693,128Jan 22, 2026Jan 26, 2026View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
2,544$0.42$1.1K719,804Nov 24, 2025Nov 26, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
43,741$0.66$28.9K722,348Oct 22, 2025Oct 24, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,792$0.59$1.1K766,089Aug 24, 2025Aug 26, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
31,866$0.48$15.3K767,881Jul 22, 2025Jul 24, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,792$0.47$848799,747May 24, 2025May 28, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
31,866$0.78$24.7K801,539Apr 22, 2025Apr 24, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
560,000560,000Feb 25, 2025Feb 26, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
120,000833,405Feb 25, 2025Feb 26, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,513$0.96$1.4K713,405Feb 25, 2025Feb 26, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,792$1.00$1.8K714,918Feb 24, 2025Feb 26, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
129,593$1.15$149.0K716,710Jan 22, 2025Jan 24, 2025View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,508$1.94$2.9K841,303Nov 25, 2024Nov 26, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,787$1.88$3.4K842,811Nov 24, 2024Nov 26, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,508$0.86$1.3K844,598Aug 25, 2024Aug 27, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,787$0.86$1.5K846,106Aug 24, 2024Aug 27, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,508$0.60$905842,893May 25, 2024May 29, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
1,787$0.60$1.1K844,401May 24, 2024May 29, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
5,010$1.13$5.7K846,188Feb 25, 2024Feb 27, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-CHIEF DEVELOPMENT OFFICER
5,474$1.13$6.2K851,198Feb 24, 2024Feb 27, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
712,500856,672Jan 22, 2024Jan 24, 2024View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-Chief Development Officer
1,462$0.38$559139,172Nov 25, 2023Nov 28, 2023View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-Chief Development Officer
1,462$0.77$1.1K140,634Aug 25, 2023Aug 29, 2023View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-Chief Development Officer
1,462$1.33$1.9K137,096May 25, 2023May 30, 2023View →
SGMO
SANGAMO THERAPEUTICS, INC
SALE
SVP-Chief Development Officer
9,834$2.66$26.2K138,558Feb 25, 2023Mar 6, 2023View →
SGMO
SANGAMO THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
53,438148,392Feb 24, 2023Mar 6, 2023View →
SGMO
SANGAMO THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
249,375249,375Feb 24, 2023Mar 6, 2023View →
Other insiders · SGMO
Loading peer insiders…
About this filer
CIK 0001947007
ROLE
SVP-Chief Development Officer
PRIMARY
SGMO
COMPANIES
1
ACTIVE SINCE
Feb 2023
MARKETPEEL · /INSIDER/0001947007DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback